ClinicalTrials.gg
CompletedNCT03453346SOF_GT2Updated Mar 7, 2018

Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C

An interventional study of Sofosbuvir and Ribavirin in Hepatitis C, Chronic and Hepatitis C Virus Infection, Response to Therapy of, sponsored by Kawin Technology Share-holding Co., Ltd.. Completed at 17 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-03-07.

Sponsored by Kawin Technology Share-holding Co., Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Aug 2016, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing sofosbuvir in Hepatitis C, Chronic — none open to participants now, 1 under way, none of them phase 3. Sofosbuvir · Hepatitis C, Chronic.

Enrollment
17th of 50
136 · median 65
Started
2016
with 4 others
No phase
5 of 50
none open now
Registered
41st of 50
by date
Lead sponsor
2 of 50
Kawin Technology Share-holding Co., Ltd.

Among the 50 studies testing sofosbuvir in Hepatitis C, Chronic, this one is the 17th largest by enrollment, is one of 5 that started in 2016, is one of 5 with no phase, and was the 41st registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 50 studies testing sofosbuvir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing sofosbuvir in Hepatitis C, Chronic as a file.
02

Study summary

This study aimed to evaluate the safety and efficacy of generic sofosbuvir, an investigational anti-hepatitis C virus (HCV) drug, combined with weight-adjusted ribavirin for treatment-naive Chinese adults chronically infected with genotype 2 HCV, the second most prevalent genotype in China. One hundred and thirty-two (132) subjects, including one hundred and twenty (120) non-cirrhotics and twelve (12) compensatory cirrhotics, were medicated with sofosbuvir 400 mg daily combined with weight-adjusted ribavirin 1000-1200 mg daily. The treatment course lasted 12 successive weeks and thereafter all the study participants entered into a 12-week treatment-free follow-up period.

Read the detailed description

It is estimated that China has a population of over 10 million infected with HCV and also a highly variable HCV genotype geographic distribution. Genotype 2 HCV is reported to be the second most common type (\~25%) in Chinese population and associated with a high risk of acute liver disease exacerbation and other extrahepatic diseases. Sofosbuvir is a pan-genotypic HCV ribonucleic acid (RNA) polymerase inhibitor directing at HCV RNA replication. Genotype 2 chronic hepatitis C has a high treatment response to the combined regimen of peginterferon and weight-adjusted ribavirin. The all-oral combination regimen of sofosbuvir and ribavirin is expected to completely suppress genotype 2 HCV replication in subjects chronically infected with HCV and achieve a sustained virologic response, namely, HCV not detected or below a predefined limit in plasma, 12 or 24 weeks after cessation of treatment.

03

Conditions studied

  • Hepatitis C, Chronic
  • Hepatitis C Virus Infection, Response to Therapy of

Keywords

  • Hepatitis C virus
  • Sofosbuvir
  • RNA polymerase inhibitor
  • Ribavirin
  • Genotype 2
  • Sustained virologic response
  • Confirmatory study
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged between 18 and 65 years (inclusive) and of either sex
  • with a (BMI) between 18 and 30 kg/m\^2
  • chronically infected with genotype 2 , and the diagnosis of chronic hepatitis C consistent with the Chinese Guideline for Prevention and Management of Hepatitis C
  • HCV RNA equaling to or above 10\^4 IU/mL and anti-HCV positivity
  • naive to anti-HCV treatment, defined as being not previously treated with any interferon (including interferon alfa or beta or peginterferon), ribavirin, or other approved, or any other not approved anti-HCV regimens of any source
  • with or without cirrhosis, presence or absence of which must be documented as at lease one item of the following: 1) liver confirming presence (e.g., Metavir score = 4 or Ishak score >=5) or absence of cirrhosis within twelve (12) months before screening; 2) FibroScan showing cirrhosis (liver stiffness modulus [LSM]>=12.5 kPa) or no cirrhosis (LSM=\<9.6 kPa); 3) a subject with a LSM of 9.6-12.5 kPa (exclusive) could only be enrolled when the liver biopsy confirmed or excluded presence of cirrhosis
  • women of without a history of menopause and with a negative blood pregnancy test; subjects of childbearing potential (including male subjects and their female partners) had no childbearing plan from screening, initiation of treatment until six (6) months after the end of treatment and consented to use effective measures
  • voluntary participation in the study and being able to understand and sign the form

Exclusion criteria

Exclusion Criteria:

  • being infected with mixed-genotype
  • having previously used any or experimental direct antiviral agents against HCV, including protease, nonstructural (NS) protein 5B polymerase or NS5A inhibitors, before screening
  • having received any interferon-based anti-HCV regimens before screening
  • having been exposed to any systemic potent immunomodulators , such as or thymosin alfa (excluding use of nasal, inhalational, topical steroids and/or others) for more than two (2) weeks within six (6) months before screening, or anticipated to be exposed to these agents during the study period
  • being coinfected with virus (HBV) or human immunodeficient virus ()
  • with evidence of decompensatory liver function, including but not limited to total serum (TBIL) above twice (2) of the (ULN), serum albumin (ALB) below 35 g/L, or prothrombin activity (PTA) below 60%; emergence of ascites, upper gastrointestinal bleeding and/or hepatic encephalopathy; with liver function reserve class B or C
  • with primary liver cancer confirmed or evidenced by serum alfa-fetoprotein above 100 ng/ml or liver imaging study showing suspected nodules
  • with a previous history of liver disease of other causes, including alcoholic liver disease, nonalcoholic steatohepatitis, drug-induced hepatitis, hepatitis (anti-nuclear antibody[ANA] titer above 1:100), Wilson disease or hemochromatosis
  • with serum alaine aminotransferase () or asparate aminotransferase (AST) above ten (10) times of ULN
  • with white blood cell (WBC) count below 3x10\^9 per liter, below 1.5x10\^9 per liter, count below 50x10\^9 per liter, or below the lower limit of the normal
  • with serum (CLcr) below 50 ml/min using the Cockcroft-Gault formula
  • with uncontrolled diabetes mellitus ([HbA1c] above 7.0%)
  • with psychiatric or neurologic disorders, including previous or family history of psychiatric disorders (especially depression, depressive state, epilepsy or hysteria)
  • with serious cardiovascular disorders, including uncontrolled hypertension (systolic blood pressure at or above 160 mmHg and/or diastolic blood pressure at or above 100 mmHg), heart insufficiency of class III or above, history of myocardial infarction within six (6) months before screening, history of percutaneous transluminal coronary angioplasty within six (6) months before screening, unstable angina pectoris, or any uncontrolled arrhythmias
  • with serious hematologic disorders (such as anemia, hemophilia and others)
  • with serious kidney diseases (such as chronic kidney disease, kidney insufficiency and others)
  • with serious gastrointestinal disorders (such as peptic ulcer, colitis and others)
  • with serious respirator disorders (such as active pulmonary tuberculosis, lung infection, , pulmonary interstitial disease and others)
  • with active or suspected malignant tumors or with a previous history of malignant tumors (excluding skin basal cell carcinoma or cervical carcinoma in situ) within five (5) years before screening
  • with a history of major organ transplantation
  • being known to be severely hypersensitive or allergic to any drugs, especially the testing medications and other constituents
  • with a history of active alcohol or drug abuse
  • being pregnant or lactating
  • being unable to discontinue prohibited medications as defined by the protocol
  • having participated in any other clinical studies within three (3) months before screening
  • being unable or unwilling to provide or unable to follow the protocol requirements
  • any other conditions of excluding a potential participant at the discretion of the investigators
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Noncirrhotic and cirrhotic GT-2

    Generic sofosbuvir tablet 400 mg once daily plus weight-adjusted ribavirin tablet (1000 mg for \<75 kg, and 1200 mg for \>=75 kg) twice daily with meal, orally given, for 12 successive weeks

    Drug: Sofosbuvir · Drug: Ribavirin

Interventions

  • Generic sofosbuvir tablet 400 mg

    Also known as: SOF

  • Ribavirin was provided in 100-mg tablets.

    Also known as: RBV

06

What researchers measure

Primary outcomes

  1. Sustained virologic response at 12 weeks after end of treatment (SVR12)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 12 weeks after end of treatment

Secondary outcomes

  1. Sustained virologic response at 4 weeks after end of treatment (SVR4)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 4 weeks after end of treatment

  2. Rapid virologic response at 1 week after initiation of treatment (RVR1)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 1 week after initiation of treatment

  3. Rapid virologic response at 2 weeks after initiation of treatment (RVR2)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 2 weeks after initiation of treatment

  4. Rapid virologic response at 4 weeks after initiation of treatment (RVR4)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 4 weeks after initiation of treatment

  5. Rapid virologic response at 8 weeks after initiation of treatment (RVR8)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 8 weeks after initiation of treatment

  6. Rapid virologic response at 12 weeks after initiation of treatment (RVR12)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 12 weeks after initiation of treatment

Other outcomes

  1. Virologic breakthrough

    Percentage of subjects with on-treatment re-detected plasma HCV RNA after HCV RNA below the lower limit of quantitation

    Time frame: 2, 4, 8 and 12 weeks after initiation of treatment

  2. Virologic relapse

    Percentage of subjects with off-treatment re-detected plasma HCV RNA after end-of-treatment HCV RNA below the lower limit of quantitation

    Time frame: 4 and 12 weeks after end of treatment

07

Study locations

17 sites
  • Chinese PLA 302 Hospital
    Beijing, Beijing 100039, China
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
  • Capital Medical University Affiliated Beijing Youyi Hospital
    Beijing, Beijing 100050, China
  • Capital Medical University Affiliated Beijing You'an Hospital
    Beijing, Beijing 100069, China
  • Capital Medical University Affiliated Beijing Ditan Hospital
    Beijing, Beijing 100102, China
  • Chongqing Medical University Affiliated Second Hospital
    Chongqing, Chongqing 400010, China
  • Chinese PLA Third Military Medical University First Affiliated Hospital
    Chongqing, Chongqing 400038, China
  • Hebei Medical University Affiliated Third Hospital
    Shijiazhuang, Hebei 50051, China
  • He'nan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
  • He'nan Provincial Hospital of Infectious Disease (Zhengzhou Municipal Sixth People's Hospital)
    Zhengzhou, Henan 450015, China
  • Nanjing Municipal Second Hospital
    Nanjing, Jiangsu 210003, China
  • Jilin University First Hospital
    Changchun, Jilin 130021, China
  • Shenyang Municipal Sixth People's Hospital
    Shenyang, Liaoning 110006, China
  • Chinese PLA Fourth Military Medical University Tangdu Hospital
    Xi'an, Shaanxi 710038, China
  • Xi'an Jiaotong University College of Medicine Affiliated First Hospital
    Xi'an, Shaanxi 710061, China
  • Qingdao Municipal Hospital
    Qingdao, Shandong 266011, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
08

References and documents

Individual participant data

Plan to share: No — No IPD sharing plan was included in the study protocol.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Mar 2017, 7 months.

Of 24 interventional studies with no phase under Hepatitis C, Chronic, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2018
First posted
Mar 5, 2018
StartActual
Aug 5, 2016
Primary completionActual
Mar 18, 2017
CompletionActual
Mar 30, 2017
Last update
Mar 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03453346
Lead sponsor
Kawin Technology Share-holding Co., Ltd.
Collaborators
KawinGreen Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Mar 5, 2018
Start date
Aug 5, 2016
Primary completion
Mar 18, 2017
Completion
Mar 30, 2017
Last update
Mar 7, 2018

Study contacts

Lai Wei, M.D.
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Ribavirin

Start the discussion